General informationGeneCopoeia has produced HEK293T cell lines expressing ACE2 and TMPRSS2, two human host factors needed for efficient infection by SARS-CoV-2, the virus responsible for the COVID-19 pandemic.
These cell lines express ACE2 and/or TMPRSS2 mRNA at high levels on the cell surface, and are amenable to infection by viruses expressing SARS-CoV-2 Spike protein in their envelopes. Refer to the “Performance data” tab for more information.
ACE2-expressing cell lines are great for use with either native SARS-CoV-2 virus or SARS-CoV-2 Spike-pseudotyped lentiviruses for several applications, such as:
- Vaccine development for prevention of infection by SARS-CoV-2 virus
- Studying the efficacy and mechanism of neutralizing antibodies against SARS-CoV-2 virus
- Development of antiviral therapeutic agents
- Studying the mechanism of virus-receptor interaction
You can order these cell lines from the table below. To obtain the datasheet for each cell line, please click on the designated catalog number.
In addition to the products below, custom stable cell lines are also available. For more information, please contact inquiry@genecopoeia.com.
For more information or to request a quote, please contact inquiry@genecopoeia.com.
Performance data
Performance data
SL221 and SL222 are cell lines derived from HEK293T that express ACE2 alone or ACE2 and TMPRSS2 mRNA at high levels, as shown in Figure 1. Expression of ACE2 protein (Figure 2) and/or TMPRSS2 protein (Figure 3) on the cell surface makes these cells amenable to infection by Spike-pseudotyped lentivirus (Figure 4).
Figure 1. Relative mRNA expression levels of ACE2 and TMPRSS2 in GeneCopoeia stable cell lines. mRNA was amplified via RT-qPCR using primers specific for each gene. Ct values of ACE2 and TMPRSS2 were normalized to Ct values for housekeeping gene GAPDH. Relative expression levels were calculated from 2^ΔΔCt. A. ACE2 mRNA expression in parental cell line HEK293T and ACE2-overexpressing HEK293T cell line SL221. B. ACE2 and TMPRSS2 mRNA expression in parental cell line HEK293T and ACE2- and TMPRSS2-overexpressing cell line SL222.
Figure 2. Immunofluorescence (IF) analysis of ACE2 protein expression on the cell surface of ACE2-expressing HEK293T cells (Cat.# SL221), ACE2/TMPRSS2 expressing HEK293T cells (Cat.# SL222), and HEK293T cells. Unpermeablized cells were fixed, blocked and incubated with the primary anti-ACE2 antibody, then washed and incubated with fluorescent-labeled secondary antibody, washed again, and stained with DAPI.
Figure 3. Immunofluorescence (IF) analysis of TMPRSS2 protein expression on the cell surface of TMPRSS2-expressing HEK293T cells (Cat.# SL222), and HEK293T cells. Unpermeablized cells were fixed, blocked and incubated with the primary anti-TMPRSS2 antibody, then washed and incubated with fluorescent-labeled secondary antibody, washed again, and stained with DAPI.
GeneCopoeia’s R&D team determined the ability of SARS-CoV-2 Spike-Pseudotyped Lentiviruses to infect ACE2-expressing cells, as shown in Figure 4.
Figure 4. ACE2- or ACE2/TMPRSS2-expressing HEK293T cells transduced by eGFP/hLuc-expressing SARS-CoV-2 Spike pseudotyped lentiviruses (pseudoviruses). 10 μl of pseudovirus was used to transduce each cell line in a 96-well plate. 72 hours after transduction, cells were photographed under fluorescence microscopy, followed by measurement of luciferase activities or FACS sorting. SL221: HEK293T cells expressing ACE2. SL222: HEK293T cells expressing ACE2 and TMPRSS2. SP101: Full-length Spike protein, D614 variant. SP103: Full-length Spike protein, D614G variant. SP001: Truncated Spike protein, D614 variant. SP003: Truncated Spike protein, D614G variant. A. Fluorescence microscopy. B. Luciferase activity assay. 20 μl of cell lysate from pseudovirus transduced cell cultures were analyzed for firefly luciferase activity using GeneCopoeia’s Luc-Pair™ Firefly Luciferase HS Assay Kit (cat. no. LF007). C. FACS sorting for determination of titer in transduction units/ml.
Resources
Webinars
Title: Advanced Tools For COVID-19 Coronavirus Research From GeneCopoeia
Presented Wednesday, September 9, 2020
The COVID-19 global pandemic, caused by the SARS-CoV-2 coronavirus, highlights an urgent need for diagnostic reagents, antiviral therapeutics, and vaccine development. In this webinar, we will discuss GeneCopoeia’s advanced solutions including testing kits, SARS-CoV-2 pseudotyped virus, and other tools needed for research into combating this deadly disease.
Watch recorded webinar / Download slides
Publications
View selected publications citing GeneCopoeia’s ACE2 receptor cell lines from the recent literature
